Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
29 hedge funds and large institutions have $236M invested in Mersana Therapeutics in 2017 Q2 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3% more ownership
Funds ownership: 0% → 3% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$113M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$28.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$21.1M |
| 5 |
PAI
ProQuest Associates IV
Naples,
Florida
|
+$13.2M |
Top Sellers
MRSN Hedge Fund Activity: Q2 2017 in Review
29 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2017, worth a combined $236M.
Buyers outnumbered sellers: 29 funds opened new MRSN positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $113M.
- 29 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $236M of Mersana Therapeutics stock for Q2 2017.
- 29 funds opened new Mersana Therapeutics positions in Q2 2017 and 0 closed out, a net change of +29 holders.
- The largest Mersana Therapeutics buyer in Q2 2017 was NEA Management Company, an estimated $113M added.
Based on aggregated 13F filings for Q2 2017.